Genmab A/S ADS (GMAB)
Stock · NASDAQ · Health Care
$33.23as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$26.27
Industry
Biotechnology: Pharmaceutical Preparations
About GMAB
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disea…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 3,119
- Website
- www.genmab.com
Fundamentals
- 1-day range
- $31.14$31.98
- Market cap
- $3.68B
- P/E (trailing)
- 25.35
- P/E (forward)
- 20.09
- EPS (trailing)
- $1.26
- Dividend yield
- —
- Beta
- 0.69
- Avg. volume
- 2.08M
52-week range
$23.22$35.43
Next earnings: November 5, 2026 · EPS estimate $0.34confirmed
Forecasts
11 analyst ratings
Buy 92%
Hold 8%
Sell 0%
1-year price forecast
High
$43.2
+30.0%
Median
$40
+20.4%
Low
$32
-3.7%
Genmab A/S ADS Competitors
Chosen by industry and closest market cap.
- GMABGenmab A/S ADS$33.23▼ 2.55%Market cap $3.68BP/E 25.35$23.22$35.43
- VKTXViking Therapeutics Inc. Common Stock$32.15▼ 5.05%Market cap $3.80BP/E —$22.96$43.15
- ELVNEnliven Therapeutics Inc. Common Stock$57.82▼ 4.43%Market cap $3.53BP/E —$14.79$62.32
- GPCRStructure Therapeutics Inc. American Depositary Shares$47.38▼ 3.74%Market cap $3.44BP/E —$18.26$94.9
- TLXTelix Pharmaceuticals Limited American Depositary Shares$11.28▼ 0.84%Market cap $3.39BP/E —$6.28$12.5
- ALMSAlumis Inc. Common Stock$22.38▼ 3.58%Market cap $3.33BP/E —$3.76$31.35
- ARQTArcutis Biotherapeutics Inc. Common Stock$23.78▼ 4.38%Market cap $3.24BP/E 113.86$15.1$31.77
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GMAB Genmab A/S ADS | $3.68B | 25.35 | $33.23 | ▼ 2.55% | $23.22$35.43 |
| VKTX Viking Therapeutics Inc. Common Stock | $3.80B | — | $32.15 | ▼ 5.05% | $22.96$43.15 |
| ELVN Enliven Therapeutics Inc. Common Stock | $3.53B | — | $57.82 | ▼ 4.43% | $14.79$62.32 |
| GPCR Structure Therapeutics Inc. American Depositary Shares | $3.44B | — | $47.38 | ▼ 3.74% | $18.26$94.9 |
| TLX Telix Pharmaceuticals Limited American Depositary Shares | $3.39B | — | $11.28 | ▼ 0.84% | $6.28$12.5 |
| ALMS Alumis Inc. Common Stock | $3.33B | — | $22.38 | ▼ 3.58% | $3.76$31.35 |
| ARQT Arcutis Biotherapeutics Inc. Common Stock | $3.24B | 113.86 | $23.78 | ▼ 4.38% | $15.1$31.77 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Genmab Stock Rises 4.4% as Drug Royalties Lift OutlookYahoo · 8/7/2026
- Guggenheim Maintains Buy on Genmab, Raises Price Target to $42Benzinga · 8/7/2026
- Genmab A/S (GMAB) Q2 2026 Earnings Call TranscriptSeekingAlpha · 8/7/2026
- Genmab (GMAB) Q2 2026 Earnings Call TranscriptYahoo · 8/7/2026
- Genmab AS (GMAB) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ...Yahoo · 8/6/2026
- Genmab A/S Q2 Earnings Call HighlightsYahoo · 8/6/2026
- Genmab shares jump 8% after upbeat results prompt 2026 outlook raiseYahoo · 8/6/2026
- Genmab Raises FY2026 Sales Guidance from $4.065B-$4.395B to $4.325B-$4.525B vs $4.355B EstBenzinga · 8/6/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 82.03M
- Total value held
- $2.23B
- Institutional holders
- 271
Top holders this quarter
- Unknown12.93M
- Unknown9.56M
- Unknown7.97M
- Unknown4.98M
- Unknown4.54M
- Unknown4.41M
- Unknown3.66M
- Unknown3.23M
- Unknown2.46M
- Unknown2.46M
See the full, filterable feed with live charts on the MarketWall dashboard.